Study reveals a significant rise in ADHD diagnoses and medication use in Finland during the COVID-19 pandemic, highlighting the pandemic’s impact on mental health recognition, especially among young women and older adults.
FDA OKs ADHD Generics; Flotation Therapy; Civilians Respond to Distress Calls
The FDA approved the first generic forms of lisdexamfetamine dimesylate (Vyvanse) capsules and chewables to treat attention deficit-hyperactivity disorder (ADHD) in patients 6 years and
August 31, 2023